SAR 55.9
(2.57%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 5.64 Million SAR | -1.22% |
2022 | 5.72 Million SAR | 20.03% |
2021 | 5.12 Million SAR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 512.13 Thousand SAR | 0.0% |
2024 Q1 | 512.13 Thousand SAR | -8.33% |
2023 Q3 | 558.69 Thousand SAR | -33.57% |
2023 Q4 | 558.69 Thousand SAR | 0.0% |
2023 FY | - SAR | -1.22% |
2023 Q2 | 841.07 Thousand SAR | -0.0% |
2023 Q1 | 841.08 Thousand SAR | -29.9% |
2022 FY | - SAR | 20.03% |
2022 Q4 | 1.19 Million SAR | 0.0% |
2021 FY | - SAR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 85.13 Million SAR | 93.364% |
Al-Dawaa Medical Services Company | 830.43 Million SAR | 99.32% |
Nahdi Medical Company | 1.64 Billion SAR | 99.656% |
Almujtama Alraida Medical Co. | 19.53 Million SAR | 71.075% |